Optimal therapy selection through precise analyses
Liquid Biopsy Monitoring
Liquid biopsy monitoring is a non-invasive method for continuously monitoring the progression of the disease in cancer patients. By analyzing circulating tumor DNA (ctDNA) in the blood, the progression of the disease and the response to therapy can be monitored in real time. In contrast to conventional biopsies, which require tissue samples, liquid biopsy offers a gentle way to detect tumor changes without surgical intervention.
Services:
- Regular liquid biopsies : Blood samples are taken several times a month or as agreed to look for circulating tumor DNA that may reveal specific mutations or resistance developments.
- Early detection of tumor changes : Changes in the tumor profile, such as the emergence of new mutations or signs of drug resistance, are detected before they become clinically manifest.
- Data-based therapy adjustment : Based on the ctDNA results, ongoing therapy can be precisely adjusted to respond to changes in the tumor.
To use:
- Non-invasive monitoring : avoidance of stressful, invasive biopsies and rapid results.
- Early detection of resistance development : Identification of tumor changes before they become clinically visible, allowing early adaptation of therapy.
- Personalized therapy adjustment in real time : Thanks to continuous monitoring, therapy decisions can be dynamically adapted to the current tumor profile.
A notice:
Liquid Biopsy Monitoring can be booked independently or in conjunction with one of our cancer packages.
Contact a Client Advisor
About: Liquid Biopsy Monitoring / Default Title